๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Combination of recombinant interferon alpha-2A and vinblastine in advanced renal cell cancer

โœ Scribed by Jean-Pierre Bergerat; Raoul Herbrecht; Patrick Dufour; Didier Jacqmin; Claude Bollack; Gilles Prevot; Georges Bailly; Steven de Garis; Franqois Juraschek; Francis Oberling

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
470 KB
Volume
62
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase II study of recombinant human al
A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer
โœ Carol M. Van Haelst-Pisani; Ronald L. Richardson; John Su; Jan C. Buckner; Richa ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 306 KB ๐Ÿ‘ 2 views

To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 x 10' U/m2 three times weekly. Toxicity was substantial and necessitated at leas

Clinical studies of recombinant interfer
Clinical studies of recombinant interferon alfa-2a (Roferonยฎ-A) in cancer patients
โœ Tetsuo Taguchi ๐Ÿ“‚ Article ๐Ÿ“… 1986 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 345 KB ๐Ÿ‘ 1 views

A Phase I study of interferon alfa-2a was conducted in 20 patients with disseminated cancer to establish the relationship between dose and interferon-related side effects. Fever was the most common side effect, and was not doserelated. Other side effects not related to dose included flu-like symptom

Treatment of advanced medullary thyroid
Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon ฮฑ-2b and octreotide
โœ Giovanni Lupoli; Edvige Cascone; Francesco Arlotta; Giovanni Vitale; Luigi Celen ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 436 KB ๐Ÿ‘ 1 views

## BACKGROUND. The medical treatment of advanced medullary thyroid carcinoma (MTC) is still questionable. Results of chemotherapy are disappointing with almost no curative responses, few partial responses, and many side-effects. A recent report has suggested the activity of combination recombinant